Holen Sie sich die Stockscreener-App
44.24
2.28%
-1.03
Handel nachbörslich:
44.36
0.12
+0.27%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$45.27
Offen:
$45
24-Stunden-Volumen:
2.62M
Relative Volume:
0.50
Marktkapitalisierung:
$11.67B
Einnahmen:
$12.98B
Nettoeinkommen (Verlust:
$1.00B
KGV:
11.13
EPS:
3.9757
Netto-Cashflow:
$287.00M
1W Leistung:
+0.59%
1M Leistung:
-15.41%
6M Leistung:
-28.89%
1J Leistung:
+38.86%
1-Tages-Spanne:
$44.16
$45.19
1-Wochen-Bereich:
$42.74
$47.03
52-Wochen-Spanne:
$28.11
$84.38
Agilent Technologies Inc Stock (AA) Company Profile
Firmenname
Agilent Technologies Inc
Sektor
Branche
Telefon
412-315-2900
Adresse
201 ISABELLA STREET, PITTSBURGH, PA
Compare AA vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AA
Agilent Technologies Inc
|
44.24 | 11.67B | 12.98B | 1.00B | 287.00M | 3.9757 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Agilent Technologies Inc Stock (AA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-08 | Fortgesetzt | Citigroup | Buy |
| 2025-05-15 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-08 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-10-23 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-10-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-09-25 | Fortgesetzt | JP Morgan | Neutral |
| 2024-09-04 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-08-12 | Hochstufung | UBS | Sell → Buy |
| 2024-08-02 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-06-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-04-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-01-16 | Eingeleitet | UBS | Sell |
| 2023-12-07 | Eingeleitet | HSBC Securities | Hold |
| 2023-10-23 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-24 | Herabstufung | Argus | Buy → Hold |
| 2023-07-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-07-11 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-06-22 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-05-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-05-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-02-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-01-19 | Bestätigt | B. Riley Securities | Neutral |
| 2022-12-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-07 | Eingeleitet | UBS | Neutral |
| 2022-09-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-09-16 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-08 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-11-17 | Eingeleitet | Wolfe Research | Outperform |
| 2021-11-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-10-05 | Bestätigt | JP Morgan | Overweight |
| 2021-09-29 | Bestätigt | Morgan Stanley | Overweight |
| 2021-09-15 | Hochstufung | Argus | Hold → Buy |
| 2021-07-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-03-03 | Hochstufung | Goldman | Sell → Buy |
| 2020-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2020-03-24 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-03-04 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2020-01-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2019-12-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-11-13 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-21 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-09-26 | Bestätigt | B. Riley FBR | Buy |
| 2019-09-23 | Herabstufung | Goldman | Buy → Neutral |
| 2019-09-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-08-16 | Bestätigt | BofA/Merrill | Neutral |
| 2019-07-19 | Herabstufung | Argus | Buy → Hold |
| 2019-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-07-09 | Herabstufung | Macquarie | Outperform → Neutral |
| 2019-04-22 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-04-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-04-02 | Herabstufung | Credit Suisse | Outperform → Neutral |
Alle ansehen
Agilent Technologies Inc Aktie (AA) Neueste Nachrichten
Agilent Technologies stock steadies as investors weigh recent earnings and life-science demand trend - AD HOC NEWS
Is Agilent Technologies (A) Undervalued Following Its FDA Approval For OPDIVO Companion Diagnostics? - Yahoo Finance UK
Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test - Yahoo Finance
Agilent Technologies Inc (A) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agilent Technologies Inc (A) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Agilent Technologies Inc (A) Institutional Confidence - TradingKey
Agilent Technologies Inc (A) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
What to Expect From Agilent Technologies' Q3 2026 Earnings Report - inkl
A|Agilent Technologies Inc|Price:139.760|Chg%:+6.300 - TradingKey
Agilent Technologies Inc|Price:138.570|Chg%:-1.185 - TradingKey
Agilent declares Q2 2026 distribution of R$ 0.44 per unit, payable July 28 - Bitget
A Look at Agilent Technologies Inc (A) After 4.7% Gain -- GF Val - GuruFocus
Agilent Technologies Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Agilent Technologies (A) Secures EU Certification for Key Diagno - GuruFocus
Why Agilent Technologies Shares Are Rising Today - Quiver Quantitative
Agilent Receives EU Certification for Keytruda Companion Diagnostic in Gynecologic Cancers - Moomoo
Agilent stock rises on EU approval for cancer diagnostic By Investing.com - Investing.com Australia
Agilent stock rises on EU approval for cancer diagnostic - Investing.com
Agilent receives EU approval for ovarian cancer diagnostic test - Investing.com
Agilent receives EU approval for ovarian cancer diagnostic test By Investing.com - Investing.com South Africa
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - Yahoo Finance
A|Agilent Technologies Inc|Price:138.965|Chg%:-0.775 - TradingKey
Agilent BDR program executes 5-for-1 stock split on ratio adjustment - Bitget
A4881169 Bond Profile — Key Metrics - TradingView
Agilent Technologies (A) Stock Forecast & Analyst Ratings - Moomoo
Agilent stock holds near report levels as earnings metrics stay in view - Ad-hoc-news.de
Agilent Technologies (NYSE:A) Gains Fresh FDA Momentum - Kalkine Media
Agilent Technologies stock trades steady as life sciences demand supports revenue outlook - Ad-hoc-news.de
[Latest] Global Metal Stamping Market Size/Share Worth USD 412.6 Billion by 2035 at a 4.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Michael Buckner Joins Agilent Technologies as Chief Legal Officer - Medical Product Outsourcing
Agilent Technologies stock trades steadily as investors weigh recent earnings and life sciences dema - Ad-hoc-news.de
Agilent increases HALO X-ray Technologies stake - Airports International
HALO X-ray Technologies Ltd announced that it has received funding from Agilent Technologies, Inc., Future Planet Capital, British Business Investments Ltd., Future Planet Capital Limited - marketscreener.com
Agilent Technologies (A) Stock Analysis: Unlocking a 21% Upside Potential with Robust Market Presence - DirectorsTalk Interviews
Agilent Technologies (A) Wells Fargo 20th Annual Healthcare Conference 2025 Summary - Quartr
Agilent Increases Its Investment in HALO X-ray Technologies - Morningstar
Agilent Technologies (A) Wins FDA Approval, Where Does Fair Value Sit Now? - Sahm
Agilent Technologies (A) Q2 2025 earnings summary - Quartr
Agilent Technologies (A) Q1 2026 earnings summary - Quartr
Agilent Technologies stock trades steady as recent earnings and life-science demand underpin valuati - Ad-hoc-news.de
Agilent Technologies (A) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
Agilent Technologies (A) Proxy Filing Summary - Quartr
Agilent Technologies (A) Q4 2025 earnings summary - Quartr
Agilent Technologies stock holds support as results stay in focus - Ad-hoc-news.de
Agilent 1260 Infinity II LC by Agilent Technologies Inc.mid-range workhorse for routine labs - Ad-hoc-news.de
Agilent Technologies Inc (A) Stock Down 3.4% -- Now Undervalued? GF Score: 93/100 - GuruFocus
Agilent Technologies Inc. stock underperforms Friday when compared to competitors - MarketWatch
Agilent Technologies stock extends focus on earnings and valuation - ad-hoc-news.de
AG8A Bond Profile — Key Metrics - TradingView
A4404722 Bond Profile — Key Metrics - TradingView
World Syringes for AgilentMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Finanzdaten der Agilent Technologies Inc-Aktie (AA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):